高危前列腺癌的转录组异质性及其对初诊时前列腺特异性膜抗原正电子发射断层显像显示前列腺外病变的意义
研究评估高危或极高危前列腺癌患者中,PSMA PET显示前列腺外病变升期风险与Decipher基因组分类评分的关联。在4625例患者队列中,两者显著相关(p < 0.001)。结果属假设生成性,需进一步研究PSMA发现、Decipher评分、前列腺外病变与长期临床结局之间的因果通路。
要点
- 高危或极高危前列腺癌患者中,PSMA PET升期风险与Decipher评分显著相关(p < 0.001)。
- 该关联基于4625例患者队列,结果属假设生成性。
- 需进一步研究PSMA发现、Decipher评分、前列腺外病变与长期结局的因果通路。
核心结论
- 在高危或极高危前列腺癌患者中,PSMA PET升期风险与Decipher基因组分类评分显著相关(p < 0.001),结果属假设生成性,需进一步研究因果通路。
研究设计与样本
- 研究纳入4625例高危或极高危前列腺癌患者,评估PSMA PET升期风险与Decipher基因组分类评分的关联。
主要发现
- 在4625例高危或极高危前列腺癌患者中,PSMA PET升期风险与Decipher评分显著相关(p < 0.001)。
局限性
- 原文指出PSMA PET发现前列腺外病变的长期临床意义未知。
- 原文指出结果应视为假设生成性,需进一步研究PSMA发现、Decipher评分、前列腺外病变与长期临床结局之间的因果通路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has greater specificity and sensitivity for detection of extraprostatic prostate cancer (PCa) at presentation than conventional imaging. Although the long-term clinical significance of acting on these findings is unknown, it has been shown that the risk of upstaging is prognostic for long-term outcomes in men with high-risk (HR) or very high-risk (VHR) PCa. We evaluated the association between the risk of upstaging on PSMA PET and the Decipher genomic classifier score, a known prognostic biomarker in localized PCa that is being evaluated for its predictive ability to direct systemic therapy intensification. In a cohort of 4625 patients with HR or VHR PCa, the risk of upstaging on PSMA PET was significantly correlated with the Decipher score (p < 0.001). These results should be seen as hypothesis-generating and warrant further studies on the causal pathways linking PSMA findings, Decipher scores, extraprostatic disease, and long-term clinical outcomes. PATIENT SUMMARY: We found significant correlation between the risk of having prostate cancer outside the prostate gland on a sensitive scan (based on prostate-specific membrane antigen [PSMA]) at initial staging and the Decipher genetic score. The results warrant further studies on the causal pathways between PSMA scan findings, Decipher scores, disease outside the prostate, and long-term outcomes.
引用
- Smith CP, Proudfoot JA, Boutros PC, et al. Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol Oncol. 2023. PMID: 36870853. doi:10.1016/j.euo.2023.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。